BioStock: Scandion Oncology tackles antioestrogen resistance

Scandion Oncology is currently evaluating its lead candidate SCO-101 in two clinical trials, one with drug resistant metastatic colorectal cancer and one as first line treatment in patients with inoperable pancreatic cancer. However, last week, the company presented a poster at the San Antonio Breast Cancer Symposium, which is the largest yearly breast cancer meeting. The poster describes the ability of SCO-101 to re-sensitise antioestrogen resistant breast cancer cells. BioStock reached out to Scandion Oncology CMO Peter Michael Vestlev and CTO Jan Stenvang to learn more about this work and its potential implications.

Read the full interview with Peter Michael Vestlev and Jan Stenvang at biostock.se:

https://www.biostock.se/en/scandion-oncology-tackles-antioestrogen-resistance/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se